Amoéba, producer of a biocontrol product for plant protection, has announced the signature of a Material Transfer Agreement (MTA) with Stähler Suisse SA. This partnership aims to extend the performance assessment of Amoéba's biocontrol products on grapes and potatoes.

Scientists say early data, generated with new NGS research panel from Thermo Fisher Scientific, suggest coronavirus is genetically stable and could increase the effectiveness of vaccines in development.

Sartorius has supported CanSino Biologics Inc. and Maj. Gen. Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials.

PerkinElmer has announced that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the company’s new Coronavirus RT-PCR test.

Designed for chemists undertaking parallel syntheses, the Asynt DrySyn 3-Position Clamp is designed to enable secure clamping of up to three round bottom flasks or condensers to a standard boss head.

InSphero has announced that it will offer free safety testing, based on human liver models, for exploratory COVID-19 medications and coronavirus (SARS-CoV-2) vaccine formulations.

Novavax, Inc. has announced positive results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older.

Informing scientists around the globe about the latest techniques in microscopy and industrial inspection at a time when face-to-face meetings are minimized, Olympus’ virtual presence at the Summit will cover microscopes, objectives, cameras – as well as equipment for X-ray fluorescence.

Heat Biologics is collaborating with the University of Miami to develop a proprietary UM COVID-19 point-of-care diagnostic test.

Vaccitech Limited and the University of Oxford have announced initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in patients with metastatic castration resistant prostate cancer (mCRPC).